Allogene Therapeutics Inc Sustainability Reports

Allogene Therapeutics, Inc. is a clinical-stage biotechnology company that focuses on pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune diseases. Its pipeline develops engineered "off-the-shelf" CAR T cell therapies aimed at delivering on-demand cell treatments on a scalable basis.

Sector: Manufacturing

Country: United States

Exchange: Nasdaq

FIGI: BBG00KHRRDY2

5 reports from 2018 to 2023

• Allogene Therapeutics Inc 2023 Environmental, Social and Governance Report
• Allogene Therapeutics Inc 2022 Environmental, Social and Governance Report
• Allogene Therapeutics Inc 2021 Form 10-K
• Allogene Therapeutics Inc 2020 Form 10-K
• Allogene Therapeutics Inc 2018 Annual Report